University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Faculty of Social and Life Sciences, Wrexham University, Wrexham, United Kingdom.
Food Nutr Bull. 2024 Jun;45(1_suppl):S40-S49. doi: 10.1177/03795721241229500.
An increasing number of adult individuals are at risk of vitamin B12 deficiency, either from reduced nutritional intake or impaired gastrointestinal B12 absorption.
This study aims to review the current best practices for the diagnosis and treatment of individuals with vitamin B12 deficiency.
A narrative literature review of the diagnosis and treatment of vitamin B12 deficiency.
Prevention and early treatment of B12 deficiency is essential to avoid irreversible neurological consequences. Diagnosis is often difficult due to diverse symptoms, marked differences in diagnostic assays' performance and the unreliability of second-line biomarkers, including holo-transcobalamin, methylmalonic acid and total homocysteine. Reduced dietary intake of B12 requires oral supplementation. In B12 malabsorption, oral supplementation is likely insufficient, and parenteral (i.e. intramuscular) supplementation is preferred. There is no consensus on the optimal long-term management of B12 deficiency with intramuscular therapy. According to the British National Formulary guidelines, many individuals with B12 deficiency due to malabsorption can be managed with 1000 µg intramuscular hydroxocobalamin once every two months after the initial loading. Long-term B12 supplementation is effective and safe, but responses to treatment may vary considerably. Clinical and patient experience strongly suggests that up to 50% of individuals require individualized injection regimens with more frequent administration, ranging from daily or twice weekly to every 2-4 weeks, to remain symptom-free and maintain a normal quality of life. 'Titration' of injection frequency based on measuring biomarkers such as serum B12 or MMA should not be practiced. There is currently no evidence to support that oral/sublingual supplementation can safely and effectively replace injections.
This study highlights the interindividual differences in symptomatology and treatment of people with B12 deficiency. Treatment follows an individualized approach, based on the cause of the deficiency, and tailored to help someone to become and remain symptom-free.
越来越多的成年人存在维生素 B12 缺乏的风险,要么是由于营养摄入减少,要么是由于胃肠道吸收 B12 能力受损。
本研究旨在综述目前诊断和治疗维生素 B12 缺乏症患者的最佳实践。
对维生素 B12 缺乏症的诊断和治疗进行叙述性文献回顾。
预防和早期治疗 B12 缺乏症对于避免不可逆的神经后果至关重要。由于症状多种多样,诊断检测的性能差异显著,以及二线生物标志物(包括全钴胺素、甲基丙二酸和总同型半胱氨酸)的可靠性较差,因此诊断常常很困难。B12 摄入减少需要口服补充。在 B12 吸收不良的情况下,口服补充可能不足,首选肌内(即肌内)补充。对于肌内治疗的 B12 缺乏症的最佳长期管理,尚无共识。根据英国国家处方集指南,许多因吸收不良而导致 B12 缺乏症的患者,在初始负荷后,可以每两个月肌内注射 1000µg 羟钴胺素一次进行管理。长期 B12 补充是有效且安全的,但治疗反应可能差异很大。临床和患者经验强烈表明,高达 50%的人需要个体化的注射方案,更频繁的给药,从每天或每周两次到每 2-4 周一次,以保持无症状并维持正常的生活质量。不应该根据测量血清 B12 或 MMA 等生物标志物来滴定注射频率。目前没有证据支持口服/舌下补充可以安全有效地替代注射。
本研究强调了 B12 缺乏症患者在症状和治疗方面的个体差异。治疗采用个体化方法,根据缺乏症的原因进行定制,以帮助患者达到并保持无症状状态。